Growth Metrics

Krystal Biotech (KRYS) Share-based Compensation (2016 - 2026)

Krystal Biotech recorded quarterly Share-based Compensation of $13.6 million in Q1 2026, down 1.13% quarter-over-quarter from $13.8 million in Q4 2025, and up 0.97% year-over-year from $13.5 million in Q1 2025.

Krystal Biotech's Share-based Compensation history runs 11 years deep, the most recent figure standing at $13.6 million for Q1 2026.

  • In Q1 2026, Share-based Compensation rose 0.97% year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $54.6 million (up 2.51% YoY), while the FY2025 annual figure was $54.5 million, up 10.97% from the prior year.
  • Share-based Compensation came in at $13.6 million for Q1 2026 at Krystal Biotech, down from $13.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $14.1 million in Q2 2025 to a low of $6.4 million in Q1 2022.
  • A 5-year average of $11.2 million and a median of $11.3 million in 2023 frame the typical range for Share-based Compensation.
  • Across the five-year window, Share-based Compensation soared 177.99% in 2022 and fell 10.9% in 2024, its largest moves.
  • Krystal Biotech's Share-based Compensation stood at $9.6 million in 2022, then grew by 3.15% to $9.9 million in 2023, then surged by 35.55% to $13.4 million in 2024, then grew by 3.05% to $13.8 million in 2025, then decreased by 1.13% to $13.6 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods registered $13.6 million, $13.8 million, and $13.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 892,057.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 305,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 166.40 Mn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 257.40 Mn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 70.15 Mn
10 Krystal Biotech 9.05 Bn 8.23 Bn 110.03 Mn 13.61 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 13.61 Mn
Mar 31, 2026 13.61 Mn
Dec 31, 2025 13.76 Mn
Dec 31, 2025 13.76 Mn
Sep 30, 2025 13.15 Mn
Sep 30, 2025 13.15 Mn
Jun 30, 2025 14.12 Mn
Jun 30, 2025 14.12 Mn
Mar 31, 2025 13.48 Mn
Mar 31, 2025 13.48 Mn
Dec 31, 2024 13.36 Mn
Dec 31, 2024 13.36 Mn
Sep 30, 2024 13.32 Mn
Sep 30, 2024 13.32 Mn
Jun 30, 2024 13.16 Mn
Jun 30, 2024 13.16 Mn
Mar 31, 2024 9.30 Mn
Mar 31, 2024 9.30 Mn
Dec 31, 2023 9.85 Mn
Dec 31, 2023 9.85 Mn
Sep 30, 2023 8.31 Mn
Sep 30, 2023 8.31 Mn
Jun 30, 2023 11.33 Mn
Jun 30, 2023 11.33 Mn
Mar 31, 2023 10.44 Mn
Mar 31, 2023 10.44 Mn
Dec 31, 2022 9.55 Mn
Dec 31, 2022 9.55 Mn
Sep 30, 2022 9.06 Mn
Sep 30, 2022 9.06 Mn
Jun 30, 2022 8.19 Mn
Jun 30, 2022 8.19 Mn
Mar 31, 2022 6.43 Mn
Mar 31, 2022 6.43 Mn
Dec 31, 2021 5.15 Mn
Dec 31, 2021 5.15 Mn
Sep 30, 2021 3.67 Mn
Sep 30, 2021 3.67 Mn
Jun 30, 2021 4.20 Mn
Jun 30, 2021 4.20 Mn
Mar 31, 2021 2.31 Mn
Mar 31, 2021 2.31 Mn
Dec 31, 2020 570,000.00
Dec 31, 2020 570,000.00
Sep 30, 2020 1.36 Mn
Sep 30, 2020 1.36 Mn
Jun 30, 2020 807,000.00
Jun 30, 2020 807,000.00
Mar 31, 2020 539,000.00
Mar 31, 2020 539,000.00
Dec 31, 2019 323,000.00
Dec 31, 2019 323,000.00
Sep 30, 2019 278,000.00
Sep 30, 2019 278,000.00
Jun 30, 2019 252,000.00
Jun 30, 2019 252,000.00
Mar 31, 2019 313,000.00
Mar 31, 2019 313,000.00
Dec 31, 2018 302,000.00
Dec 31, 2018 302,000.00
Sep 30, 2018 168,000.00
Sep 30, 2018 168,000.00
Jun 30, 2018 110,000.00
Jun 30, 2018 110,000.00
Mar 31, 2018 65,000.00
Mar 31, 2018 65,000.00
Dec 31, 2017 58,000.00
Dec 31, 2017 58,000.00
Sep 30, 2017 54,000.00
Sep 30, 2017 54,000.00
Jun 30, 2017 44,000.00
Jun 30, 2017 44,000.00
Mar 31, 2017 91,000.00
Mar 31, 2017 91,000.00
Dec 31, 2016 26,000.00
Dec 31, 2016 26,000.00
Sep 30, 2016 4,000.00
Sep 30, 2016 4,000.00